{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T05:08:26Z","timestamp":1737436106345,"version":"3.33.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pediatric Surgery"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.jpedsurg.2007.03.041","type":"journal-article","created":{"date-parts":[[2007,8,15]],"date-time":"2007-08-15T11:15:04Z","timestamp":1187176504000},"page":"1396-1402","source":"Crossref","is-referenced-by-count":5,"title":["In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma"],"prefix":"10.1016","volume":"42","author":[{"given":"David A.","family":"Rodeberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Erskine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Celis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpedsurg.2007.03.041_bib1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1056\/NEJM199907293410507","article-title":"Common musculoskeletal tumors of childhood and adolescence","volume":"341","author":"Arndt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib2","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.1995.13.3.610","article-title":"The Third Intergroup Rhabdomyosarcoma Study","volume":"13","author":"Crist","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1084\/jem.186.1.65","article-title":"Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help","volume":"186","author":"Bennett","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib4","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1084\/jem.186.8.1183","article-title":"Dendritic cells as adjuvants for immune-mediated resistance to tumors","volume":"186","author":"Schuler","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib5","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide\u2014or tumor lysate-pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib6","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/42716","article-title":"A dendritic cell derived C-C chemokine that preferentially attracts naive T cells","volume":"387","author":"Adema","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib7","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.4049\/jimmunol.154.10.5071","article-title":"Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells","volume":"154","author":"Macatonia","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib8","first-page":"53","article-title":"Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects","volume":"4","author":"Fernandez","year":"1998","journal-title":"Cytokines Cell Mol Ther"},{"issue":"17","key":"10.1016\/j.jpedsurg.2007.03.041_bib9","first-page":"6451","article-title":"Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine","volume":"61","author":"Banchereau","year":"2001","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.jpedsurg.2007.03.041_bib10","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood.V93.7.2411","article-title":"Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma\u2014a feasibility study","volume":"93","author":"Reichardt","year":"1999","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jpedsurg.2007.03.041_bib11","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1200\/JCO.2000.18.23.3894","article-title":"Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells","volume":"18","author":"Small","year":"2000","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jpedsurg.2007.03.041_bib12","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1084\/jem.190.11.1669","article-title":"Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma","volume":"190","author":"Thurner","year":"1999","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.jpedsurg.2007.03.041_bib13","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.V99.5.1517","article-title":"Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients","volume":"99","author":"Timmerman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0952-7915(94)90078-7","article-title":"MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy","volume":"6","author":"Topalian","year":"1994","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib15","first-page":"5223","article-title":"Use of two predictive algorithms of the World Wide Web for the identification of tumor-reactive T-cell epitopes","volume":"60","author":"Lu","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib16","first-page":"5228","article-title":"Defining promiscuous MHC class II helper T-cell epitopes for the HER2\/Neu tumor antigen","volume":"60","author":"Kobayashi","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib17","first-page":"4773","article-title":"Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-3 epitope presented by various major histocompatibility complex class II alleles","volume":"61","author":"Kobayashi","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib18","first-page":"3219","article-title":"Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen","volume":"8","author":"Kobayashi","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jpedsurg.2007.03.041_bib19","first-page":"169","article-title":"Development of vaccines against self-antigens: the p53 paradigm","volume":"6","author":"Chada","year":"2003","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"5","key":"10.1016\/j.jpedsurg.2007.03.041_bib20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2174\/1568009043332916","article-title":"Carcinoembryonic antigen as a target to induce anti-tumor immune responses","volume":"4","author":"Sarobe","year":"2004","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s002620000169","article-title":"A listing of human tumor antigens recognized by T cells","volume":"50","author":"Renkvist","year":"2001","journal-title":"Cancer Immunol Immunother"},{"issue":"25","key":"10.1016\/j.jpedsurg.2007.03.041_bib22","doi-asserted-by":"crossref","first-page":"14523","DOI":"10.1073\/pnas.96.25.14523","article-title":"STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors","volume":"96","author":"Hubert","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"10.1016\/j.jpedsurg.2007.03.041_bib23","first-page":"5857","article-title":"Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice","volume":"61","author":"Yang","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib24","first-page":"5443","article-title":"Predominant expression of alternative PAX3 and PAX7 forms in myogenic and neural tumor cell lines","volume":"59","author":"Barr","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib25","first-page":"823","article-title":"PAX3 is expressed in human melanomas and contributes to tumor cell survival","volume":"61","author":"Scholl","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib26","first-page":"8105","article-title":"Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization","volume":"61","author":"Kotera","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib27","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1073\/pnas.91.6.2105","article-title":"Induction of antitumor cytotoxic t lymphocytes in normal humans using primary cultures and synthetic peptide epitopes","volume":"91","author":"Celis","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib28","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.4049\/jimmunol.166.12.7063","article-title":"TAP-independent presentation of CTL epitopes by Trojan antigens","volume":"166","author":"Lu","year":"2001","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.jpedsurg.2007.03.041_bib29","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1182\/blood.V96.9.3102","article-title":"Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells","volume":"96","author":"Brossart","year":"2000","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jpedsurg.2007.03.041_bib30","doi-asserted-by":"crossref","first-page":"9482","DOI":"10.1073\/pnas.95.16.9482","article-title":"Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo","volume":"95","author":"Fields","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib31","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood.V96.5.1857","article-title":"Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte responses","volume":"96","author":"Herr","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jpedsurg.2007.03.041_bib32","first-page":"1028","article-title":"Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells","volume":"60","author":"Boczkowski","year":"2000","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.jpedsurg.2007.03.041_bib33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nm0398-321","article-title":"Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma","volume":"4","author":"Rosenberg","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib34","first-page":"2336","article-title":"Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements","volume":"8","author":"Huarte","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jpedsurg.2007.03.041_bib35","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.2003.09.020","article-title":"Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses","volume":"21","author":"Smith","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib36","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00262-002-0328-9","article-title":"Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues","volume":"51","author":"Tsuboi","year":"2002","journal-title":"Cancer Immunol Immunother"},{"issue":"16","key":"10.1016\/j.jpedsurg.2007.03.041_bib37","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.4049\/jimmunol.166.6.3678","article-title":"Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells","volume":"166","author":"Ludewig","year":"2001","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.jpedsurg.2007.03.041_bib38","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/(SICI)1097-0215(19960516)66:4<470::AID-IJC10>3.0.CO;2-C","article-title":"Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8(+) cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo","volume":"66","author":"Jager","year":"1996","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.jpedsurg.2007.03.041_bib39","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00262-004-0542-8","article-title":"Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination","volume":"53","author":"Galea-Lauri","year":"2004","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.jpedsurg.2007.03.041_bib40","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00262-002-0339-6","article-title":"Analysis of in vitro immunization: generation of cytotoxic T-lymphocytes against allogeneic melanoma cells with tumor lysate-loaded or tumor RNA-transfected antigen-presenting cells","volume":"52","author":"Glazyrin","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jpedsurg.2007.03.041_bib41","first-page":"8513","article-title":"Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression","volume":"61","author":"Geiger","year":"2001","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.jpedsurg.2007.03.041_bib42","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00262-004-0577-x","article-title":"Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?","volume":"53","author":"Malmberg","year":"2004","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.jpedsurg.2007.03.041_bib43","first-page":"623","article-title":"Perspective on allogeneic melanoma lysates in active specific immunotherapy","volume":"25","author":"Mitchell","year":"1998","journal-title":"Semin Oncol"},{"issue":"23","key":"10.1016\/j.jpedsurg.2007.03.041_bib44","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1200\/JCO.2002.01.151","article-title":"Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine","volume":"20","author":"Hsueh","year":"2002","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.jpedsurg.2007.03.041_bib45","first-page":"3782","article-title":"Protective antitumor immunity induced by immunization with completely allogeneic tumor cells","volume":"56","author":"Toes","year":"1996","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jpedsurg.2007.03.041_bib46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.2001.19.1.145","article-title":"Novel allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation","volume":"19","author":"Jaffee","year":"2001","journal-title":"J Clin Oncol"}],"container-title":["Journal of Pediatric Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022346807001820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022346807001820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T10:24:36Z","timestamp":1737368676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022346807001820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0022346807001820"],"URL":"https:\/\/doi.org\/10.1016\/j.jpedsurg.2007.03.041","relation":{},"ISSN":["0022-3468"],"issn-type":[{"type":"print","value":"0022-3468"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}